-$0.14 Earnings Per Share Expected for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) This Quarter

Equities research analysts expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) to post earnings of ($0.14) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Corvus Pharmaceuticals’ earnings. Corvus Pharmaceuticals posted earnings of ($0.34) per share in the same quarter last year, which would indicate a positive year over year growth rate of 58.8%. The business is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.89) to ($0.79). For the next year, analysts expect that the firm will report earnings of ($1.56) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) last posted its earnings results on Thursday, March 10th. The company reported ($0.20) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.20). During the same quarter in the prior year, the company earned ($0.35) earnings per share.

CRVS has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Corvus Pharmaceuticals in a report on Friday, March 11th. StockNews.com initiated coverage on shares of Corvus Pharmaceuticals in a report on Thursday, March 31st. They set a “sell” rating for the company. Finally, Zacks Investment Research downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, March 15th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Corvus Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $5.55.

In related news, CFO Leiv Lea bought 35,160 shares of the business’s stock in a transaction that occurred on Wednesday, March 16th. The stock was purchased at an average cost of $1.54 per share, for a total transaction of $54,146.40. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Richard A. Md Miller bought 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 15th. The shares were bought at an average price of $1.47 per share, with a total value of $36,750.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 80,160 shares of company stock valued at $123,446. Corporate insiders own 45.12% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Barclays PLC raised its stake in shares of Corvus Pharmaceuticals by 1,159,200.0% in the 4th quarter. Barclays PLC now owns 11,593 shares of the company’s stock valued at $28,000 after buying an additional 11,592 shares in the last quarter. Zacks Investment Management acquired a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at $48,000. Coastal Bridge Advisors LLC acquired a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at $58,000. Walleye Capital LLC acquired a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at $64,000. Finally, Lindbrook Capital LLC acquired a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at $68,000. Institutional investors own 77.86% of the company’s stock.

NASDAQ CRVS opened at $1.31 on Wednesday. The company has a fifty day simple moving average of $1.60 and a 200 day simple moving average of $2.55. Corvus Pharmaceuticals has a 1 year low of $1.28 and a 1 year high of $9.54.

About Corvus Pharmaceuticals (Get Rating)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.

See Also